Distinguishing Mast Cell Activation Syndrome (MCAS) from mastocytosis based solely on clinical signs and symptoms presents a significant diagnostic challenge, as both conditions share overlapping manifestations related to mast cell mediator release. However, understanding the nuances of their clinical presentations, along with the context of symptom patterns, can provide important clues for differentiation.
Table of contents
- Understanding the fundamental differences
- Cutaneous manifestations: A critical distinguishing feature
- Pattern and severity of symptom presentation
- Gastrointestinal and systemic symptoms
- Cardiovascular and anaphylactic presentations
- Specific organ system involvement
- The challenge of symptom overlap and diagnostic limitations
- The necessity of laboratory and histopathological confirmation
- Clinical approach and red flags
- Conclusion
- References:
Understanding the fundamental differences
Mastocytosis represents a clonal disorder characterised by the pathological accumulation and proliferation of neoplastic mast cells in one or more organ systems, most commonly the skin and bone marrow [1]. This condition is often associated with the somatic gain-of-function KIT D816V mutation, which is found in approximately 90-95% of cases [2]. In contrast, MCAS is defined by episodic and systemic activation of mast cells without the gross mast cell neoplasia characteristic of mastocytosis [3]. MCAS can be further classified into primary (clonal), secondary (IgE-mediated or triggered by known stimuli), and idiopathic forms, each with distinct underlying mechanisms [4].
Cutaneous manifestations: A critical distinguishing feature
The presence or absence of specific skin lesions provides one of the most important clinical differentiators between these conditions. Systemic mastocytosis (SM) is frequently associated with cutaneous involvement, particularly urticaria pigmentosa, which presents as red-brown macules or papules that demonstrate a positive Darier sign (urticaria and erythema following stroking of the lesion) [5]. This pathognomonic sign is characteristic of cutaneous mastocytosis and helps establish the diagnosis in patients with skin involvement [6]. In paediatric populations, cutaneous mastocytosis is the most common form, with maculopapular cutaneous mastocytosis (MPCM) presenting as the typical variant, while mastocytoma appears as solitary nodular plaques, and diffuse cutaneous mastocytosis (DCM) represents a rare but severe form with erythroderma and blistering [7].
However, it is crucial to recognise that systemic mastocytosis can occur without cutaneous features, making the diagnosis particularly challenging in these cases [8]. When SM presents without skin lesions, the clinical manifestations become much more similar to MCAS, and differentiation based on symptoms alone becomes extremely difficult. In contrast, MCAS typically does not present with the fixed pigmented skin lesions characteristic of mastocytosis, though patients may experience episodic flushing, urticaria, and angioedema during mast cell activation episodes [9].
Pattern and severity of symptom presentation
The temporal pattern and severity of symptoms offer important diagnostic insights. MCAS is characterised by severe, recurrent, episodic symptoms that are typical of mast cell activation and involve at least two organ systems simultaneously [10]. The prototypical presentation resembles idiopathic anaphylaxis, with symptoms including flushing, urticaria, angioedema, bronchospasm, gastrointestinal disturbances (abdominal pain, nausea, vomiting, diarrhoea), and in severe cases, hypotension and cardiovascular collapse [11]. These episodes are characteristically intermittent and may be triggered by various stimuli, including foods, medications, physical factors, or may occur spontaneously [12].
Mastocytosis patients can also experience mediator-related symptoms similar to MCAS, termed mast cell activation syndrome in the context of mastocytosis, which may present as a primary or mixed (primary and secondary) form [9]. The clinical presentation varies significantly depending on the mastocytosis subtype, ranging from asymptomatic patients to life-threatening disease with multiple organ involvement leading to cytopenia, malabsorption, hepatosplenomegaly, lymphadenopathy, ascites, or osteolytic bone lesions with pathological fractures [1]. In advanced forms such as aggressive systemic mastocytosis (ASM) and mast cell leukaemia (MCL), symptoms related to organ infiltration by neoplastic mast cells become prominent, which is not a feature of MCAS [13].
Gastrointestinal and systemic symptoms
Both conditions can present with gastrointestinal manifestations, but certain patterns may suggest one diagnosis over the other. MCAS patients commonly report digestive symptoms, including flatulence, diarrhoea, heartburn, and nausea, with studies showing that flatulence occurs in approximately 83.5% of hereditary alpha-tryptasemia (HaT) patients and diarrhoea in 68.8% of SM patients [14]. Nausea appears more frequently in HaT patients compared to SM patients, occurring in 51.7% versus 21.9% respectively [14]. When mastocytosis is isolated to the gastrointestinal tract without cutaneous involvement, the symptoms are often non-specific and can mimic inflammatory bowel disease or irritable bowel syndrome, making clinical diagnosis particularly challenging [8].
Neuropsychiatric symptoms also show differential patterns, with patients having HaT reporting these complaints more frequently than those with SM or control populations. Memory impairment, sleep disturbances, and fatigue are significantly more common in certain mast cell disorder subtypes [14]. MCAS has been associated with various neurologic and psychiatric disorders, including headache, dysautonomia, depression, generalised anxiety disorder, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, phobias, and bipolar disorder [15]. Many of these neuropsychiatric manifestations may be refractory to standard treatments but respond to mast-cell-directed therapy [15].
Cardiovascular and anaphylactic presentations
Severe cardiovascular symptoms, particularly hypotension and syncope, can occur in both conditions but may have different underlying mechanisms. Mastocytosis patients can experience episodic flushing and severe hypotension due to massive mediator release, with some cases presenting with syncope as a prominent feature [5]. In one reported case, a patient demonstrated marked neutrophilia and reduced blood potassium concentrations soon after the onset of each episode, which could last several hours and occur once to four times annually [5]. The presence of recurrent unexplained hypotension or syncope should raise suspicion for either SM or MCAS, though neither can be definitively diagnosed without additional investigations [5].
MCAS characteristically presents with anaphylaxis or anaphylaxis-like episodes, with the typical clinical pattern involving idiopathic anaphylaxis [10]. Patients experience sudden onset of symptoms affecting multiple organ systems, meeting criteria for anaphylactic response, but without clearly identifiable triggers in the idiopathic form [3]. The frequency and severity of these episodes can vary considerably among patients, and some may require emergency treatment with epinephrine autoinjectors [10].
Specific organ system involvement
Respiratory symptoms including wheezing, dyspnoea, and in MCAS cases, symptoms meeting anaphylaxis criteria such as throat tightness and difficulty breathing, are common to both conditions [11]. However, the pattern of respiratory involvement may differ. MCAS typically presents with acute bronchospasm during activation episodes, while mastocytosis patients may have more persistent respiratory symptoms if there is pulmonary infiltration by mast cells, though this is less common [16].
Musculoskeletal symptoms are reported in both conditions, with bone pain being a particular concern in mastocytosis, where osteolytic lesions and pathological fractures can occur due to mast cell infiltration [1]. This represents a distinguishing feature, as MCAS does not cause structural bone disease, though patients may experience diffuse musculoskeletal pain related to mediator release and associated conditions [15].
The challenge of symptom overlap and diagnostic limitations
A critical limitation in relying solely on signs and symptoms for differentiation is the significant overlap in mediator-related manifestations. Both conditions can present with flushing, pruritus, urticaria, angioedema, abdominal cramping, diarrhoea, headache, and, in severe cases, anaphylaxis [16]. The symptoms in both cases result from the release of mast cell mediators, including histamine, tryptase, heparin, prostaglandins, and leukotrienes, which affect multiple organ systems regardless of whether the underlying disorder is clonal proliferation or aberrant activation [17].
Furthermore, the distinction between primary (clonal) MCAS and mastocytosis can be particularly challenging, as primary MCAS is defined by clonal expansion of mast cells proceeding as confirmed systemic mastocytosis or meeting two minor criteria for mastocytosis [3]. In these cases, the clinical presentations are virtually indistinguishable without bone marrow examination and molecular testing [18]. Some patients initially diagnosed with MCAS may eventually progress to systemic mastocytosis, with studies showing that up to 23.4% of MCAS patients progressed to SM, and notably, all patients with KIT mutations eventually developed SM [19].
The necessity of laboratory and histopathological confirmation
While this discussion has focused on clinical signs and symptoms, it is essential to emphasise that definitive differentiation between MCAS and mastocytosis cannot reliably be made on clinical grounds alone. The consensus diagnostic criteria for both conditions require laboratory evidence, and for mastocytosis, histopathological confirmation [11]. The Vienna Consensus criteria for MCAS include clinical criteria (severe recurrent symptoms involving two or more organs meeting anaphylaxis criteria), laboratory criteria (significant increase in serum tryptase during episodes), and therapeutic response criteria [3]. Mastocytosis diagnosis requires meeting WHO criteria including major criteria (multifocal dense mast cell infiltrates in bone marrow or other extracutaneous organs) and minor criteria including abnormal mast cell morphology, KIT mutation detection, elevated baseline serum tryptase, and aberrant mast cell surface marker expression [20].
Clinical approach and red flags
In clinical practice, certain patterns should raise higher suspicion for one diagnosis over the other. The presence of persistent pigmented skin lesions with positive Darier sign strongly suggests mastocytosis rather than MCAS [21]. Conversely, recurrent episodes of idiopathic anaphylaxis without skin lesions or organomegaly are more consistent with MCAS, though SM without cutaneous involvement must still be excluded [10]. Significantly elevated baseline serum tryptase levels (greater than 20 ng/mL) serve as a minor criterion for systemic mastocytosis and should prompt further investigation including bone marrow examination, though elevated tryptase alone is not diagnostic and can be seen in hereditary alpha-tryptasemia [20].
The presence of hepatosplenomegaly, lymphadenopathy, or unexplained cytopenias suggests systemic mastocytosis with organ involvement rather than MCAS, as these findings indicate mast cell infiltration causing organ dysfunction [22]. In contrast, MCAS patients typically do not have persistent organomegaly or cytopenias outside of acute activation episodes unless there is concurrent disease [3].
Conclusion
Differentiating MCAS from mastocytosis based on signs and symptoms alone is inherently challenging and often unreliable due to the significant overlap in mediator-related manifestations. The presence of characteristic cutaneous lesions (urticaria pigmentosa with positive Darier sign) strongly suggests mastocytosis, while their absence does not exclude the diagnosis. The pattern of symptoms—whether episodic with complete resolution between events (more typical of MCAS) versus persistent or progressive with organ involvement (more suggestive of advanced mastocytosis)—can provide clinical clues. However, definitive diagnosis requires integration of clinical presentation with laboratory markers (particularly tryptase measurements during and between episodes), genetic testing for KIT mutations, and in many cases, bone marrow examination with immunohistochemistry and flow cytometry [18]. Clinicians should maintain a low threshold for comprehensive diagnostic workup in patients presenting with recurrent unexplained systemic symptoms suggestive of mast cell activation, as accurate diagnosis is essential for appropriate management and prognostication [22].
Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice.
References:
[7] H. ugowskaUmer, J. Czarny, A. Rydz, R. Nowicki, and M. Lange, “Current Challenges in the Diagnosis of Pediatric Cutaneous Mastocytosis,” Multidisciplinary Digital Publishing Institute, Dec. 2023, doi:https://www.mdpi.com/2075-4418/13/23/3583
[15] L. B. Weinstock, R. M. Nelson, and S. Blitshteyn, “Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series,” Multidisciplinary Digital Publishing Institute, Oct. 2023, doi: https://www.mdpi.com/2075-4426/13/11/1562
[17] D. E. A. Komi, T. Rambasek, and S. Whrl, “Mastocytosis: from a Molecular Point of View,” Springer Nature, Jul. 2017, doi: https://link.springer.com/article/10.1007/s12016-017-8619-2
[18] T. Glen et al., “Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review,” Elsevier BV, Jun. 2021, doi: https://www.jaci-inpractice.org/article/S2213-2198(21)00676-0/fulltext
